Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 Monotherapy at 1.5 mCi in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma
Perspective Therapeutics, Inc. (CATX)
Company Research
Source: GlobeNewswire
SEATTLE, April 11, 2025 (GLOBE NEWSWIRE) -- Perspective, Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, announced today that the first patient was dosed in a new cohort of a Phase 1/2a trial evaluating the safety of [212Pb]VMT01, a targeted alpha-particle therapy (TAT), as monotherapy in patients with histologically confirmed melanoma and positive melanocortin 1 receptor (MC1R) imaging scans. Patients in this cohort are receiving [212Pb]VMT01 at 1.5 mCi as monotherapy. Initial results from the earlier monotherapy cohorts were previously presented at the 21st International Congress of the Society for Melanoma Research (SMR) in October 2024. A cohort administering a combination regimen with the immune checkpoint inhibitor nivolumab commenced dosing in March 2025. "This further dose finding of [212Pb]VMT01 as monotherapy in patients with metastatic melanoma follo
Show less
Read more
Impact Snapshot
Event Time:
CATX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CATX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CATX alerts
High impacting Perspective Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CATX
News
- Perspective Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswire
- Perspective Therapeutics Announces Acceptance of VMT-a-NET Data for Presentation at the ASCO Gastrointestinal Cancers SymposiumGlobeNewswire
- Perspective Therapeutics (NASDAQ:CATX) is now covered by analysts at Truist Financial Corporation. They set a "buy" rating and a $12.00 price target on the stock.MarketBeat
- Perspective Therapeutics (NASDAQ:CATX) had its price target lowered by analysts at B. Riley from $12.00 to $11.00. They now have a "buy" rating on the stock.MarketBeat
- Perspective Therapeutics (NASDAQ:CATX) had its price target lowered by analysts at UBS Group AG from $18.00 to $7.00. They now have a "buy" rating on the stock.MarketBeat
CATX
Earnings
- 11/10/25 - Miss
CATX
Sec Filings
- 12/5/25 - Form SCHEDULE
- 12/1/25 - Form 8-K
- 11/17/25 - Form 4
- CATX's page on the SEC website